TCIM
INSY

TIAA CREF Investment Management’s Insys Therapeutics, Inc. INSY Stock Holding History

TIAA CREF Investment Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$245K Buy
52,971
+1,194
+2% +$5.65K ﹤0.01% 2846
2018
Q4 		$181K Sell
51,777
-1,186
-2% -$8.24K ﹤0.01% 2894
2018
Q3 		$534K Sell
52,963
-1,619
-3% -$12.9K ﹤0.01% 2687
2018
Q2 		$395K Sell
54,582
-1,446
-3% -$10.1K ﹤0.01% 2871
2018
Q1 		$338K Sell
56,028
-6,452
-10% -$53.3K ﹤0.01% 2880
2017
Q4 		$601K Sell
62,480
-1,568
-2% -$10.3K ﹤0.01% 2691
2017
Q3 		$569K Hold
64,048
– – ﹤0.01% 2774
2017
Q2 		$810K Buy
64,048
+2,250
+4% +$26.6K ﹤0.01% 2646
2017
Q1 		$649K Sell
61,798
-2,410
-4% -$25.7K ﹤0.01% 2700
2016
Q4 		$591K Sell
64,208
-5,261
-8% -$59.4K ﹤0.01% 2784
2016
Q3 		$819 Sell
69,469
-1,985
-3% -$30.2K ﹤0.01% 2640
2016
Q2 		$925K Sell
71,454
-40,609
-36% -$592K ﹤0.01% 2548
2016
Q1 		$1.79M Sell
112,063
-214,997
-66% -$4.08M ﹤0.01% 2136
2015
Q4 		$9.36M Sell
327,060
-5,908
-2% -$164K 0.01% 1107
2015
Q3 		$9.48M Sell
332,968
-25,982
-7% -$956K 0.01% 1078
2015
Q2 		$12.9M Sell
358,950
-102,460
-22% -$3.19M 0.01% 989
2015
Q1 		$13.4M Buy
461,410
+389,546
+542% +$10.3M 0.01% 962
2014
Q4 		$1.51M Sell
71,864
-1,900
-3% -$37.6K ﹤0.01% 2420
2014
Q3 		$1.43M Sell
73,764
-3,238
-4% -$50.8K ﹤0.01% 2436
2014
Q2 		$1.2M Buy
77,002
+12,904
+20% +$209K ﹤0.01% 2609
2014
Q1 		$1.33M Sell
64,098
-8,850
-12% -$176K ﹤0.01% 2476
2013
Q4 		$941K Buy
72,948
+23,430
+47% +$325K ﹤0.01% 2708
2013
Q3 		$578K Buy
49,518
+5,670
+13% +$46.5K ﹤0.01% 2893
2013
Q2 		$202K Buy
+43,848
New +$161K ﹤0.01% 3042

Other funds holding INSY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

TIAA CREF Investment Management's INSY Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Insys Therapeutics, Inc. (INSY) stake by 2.3% in Q1 2019, buying an estimated $5.65K and bringing the position to 52,971 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #2846.

TIAA CREF Investment Management first reported a position in INSY in Q2 2013 and has held it in 24 quarters since. The position peaked at $13.4M in Q1 2015. 98 funds tracked by Wall St. Rank hold INSY as of Q1 2019.

  • TIAA CREF Investment Management held 52,971 shares of Insys Therapeutics, Inc. worth $245K as of Q1 2019.
  • TIAA CREF Investment Management bought 1,194 Insys Therapeutics, Inc. shares in Q1 2019, an estimated $5.65K.
  • Insys Therapeutics, Inc. made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2846 holding.
  • TIAA CREF Investment Management first reported a position in Insys Therapeutics, Inc. in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Insys Therapeutics, Inc. position peaked at $13.4M in Q1 2015.
  • 98 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.